DZ Bank’s Iovance Biotherapeutics IOVA Stock Holding History

DZ Bank’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-42,740	Closed	-$722K	–	960
2018 Q1	$722K	Buy	+42,740	New	+$647K	﹤0.01%	725

Other funds holding IOVA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DZ Bank's IOVA Position: Q2 2018 in Review

DZ Bank sold out of Iovance Biotherapeutics (IOVA) in Q2 2018, closing a stake of 42,740 shares — an estimated $722K sold.

DZ Bank first reported a position in IOVA in Q1 2018 and held it in 1 quarter. The position peaked at $722K in Q1 2018. 126 funds tracked by Wall St. Rank hold IOVA as of Q2 2018.

DZ Bank reported no remaining Iovance Biotherapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 42,740 Iovance Biotherapeutics shares in Q2 2018, an estimated $722K.
DZ Bank first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Iovance Biotherapeutics position peaked at $722K in Q1 2018.
126 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.